evidence: The ongoing COVID-19 pandemic has claimed >4 million lives globally, and these deaths often occurred in hospitalized patients with comorbidities. Therefore, the proposed review aims to distinguish the inpatient mortality and invasive mechanical ventilation risk in COVID-19 patients treated with the anti-SARS-CoV-2 monoclonal antibodies and/or the antiviral agents. [...] Citation: Saha S (2022) Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. PLoS ONE 17(6): e0270196. https://doi.org/10.1371/journal.pone.0270196 [...] - Outcome: The primary outcome of interest will be all-cause inpatient deaths. The secondary outcome will include eventual invasive mechanical ventilation requirements in hospitalized COVID-19 patients. A trial must report either one or both of these outcomes to be eligible.